The Ogawa-Yamanaka Stem Cell Prize recognizes individuals whose original translational research has advanced cellular reprogramming technology for regenerative medicine.
The prize was established in 2015 through a generous gift from the late Hiro and Betty Ogawa and is supported by Gladstone Institutes. It recognizes the importance of induced pluripotent stem (iPS) cells, discovered by Gladstone Senior Investigator and Nobel Laureate Shinya Yamanaka.
In the midst of the ongoing pandemic and the shift in focus from members of the scientific community to advancing discoveries related to COVID-19, the Ogawa-Yamanaka Stem Cell Prize committee decided to forego choosing a 2020 recipient. Nominations will resume for the next round in January 2021.
Gladstone is proud to partner with Cell Press group to support this important prize.
Each year, the awardee is honored during a ceremony hosted by Gladstone Institutes in San Francisco, California. The recipient gives a scientific lecture and is presented with the award, along with an unrestricted prize of $150,000 USD.
Gordon Keller, PhDDirector of the McEwen Stem Cell Institute at the University Health Network, Senior Scientist at Princess Margaret Cancer Centre, Professor of Medical Biophysics at the University of Toronto
Keller was selected for his life-long contributions to the efficient, lineage-specific differentiation of human pluripotent stem cells into a myriad of cell types. His work enables disease modeling and regenerative medicine approaches for many human diseases.
Marius Wernig, MD, PhDAssociate Professor at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University
Wernig was selected for his innovative direct neuronal reprogramming technology, and for his contributions to the advancement of therapies for genetic diseases based on iPS cells”. His groundbreaking research has advanced the development of disease models for neurological diseases and skin disorders.
Lorenz P. Studer, MDDirector of the Center for Stem Cell Biology and member of the Developmental Biology Program at the Memorial Sloan Kettering Cancer Center
A distinguished stem cell biologist, Studer was selected for his transformative contributions to the field of cellular reprogramming and the application of human iPS cells to human disease. His groundbreaking research has advanced the therapeutic potential of stem cell–based therapies in Parkinson’s disease and other neurological disorders.
Douglas Melton, PhDCo-director of the Harvard Stem Cell Institute, Xander University Professor at Harvard University, Investigator of the Howard Hughes Medical Institute
Melton was honored for his research that led to a novel way to reprogram human stem cells into insulin-producing beta cells. His work provides the foundation for the ultimate goal of transplanting patient-specific beta cells to treat diabetes.
Masayo Takahashi, MD, PhDProject Leader, Laboratory for Retinal Regeneration at the RIKEN Centre for Developmental Biology
Takahashi was honored for her trailblazing research that led to the first clinical trial to use induced pluripotent stem (iPS) cells in humans. Her work paves the way for using stem cells to treat retinal diseases, including macular degeneration.